Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model.
about
Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseasesHistone deacetylase 3 (HDAC 3) as emerging drug target in NF-κB-mediated inflammationNeuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury.Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and UnRegulation of lipopolysaccharide-induced inflammatory response and endotoxemia by beta-arrestinsBlocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signalingModulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock.Enhancement of inflammatory protein expression and nuclear factor Κb (NF-Κb) activity by trichostatin A (TSA) in OP9 preadipocytesHistone deacetylase inhibitors for treating a spectrum of diseases not related to cancerEpigenetic modifiers reduce inflammation and modulate macrophage phenotype during endotoxemia-induced acute lung injury.Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock.Treatment with histone deacetylase inhibitor attenuates MAP kinase mediated liver injury in a lethal model of septic shock.Inhibition of histone deacetylases in inflammatory bowel diseases.Macrophage polarization in response to epigenetic modifiers during infection and inflammation.The histone deacetylase inhibitors MS-275 and SAHA suppress the p38 mitogen-activated protein kinase signaling pathway and chemotaxis in rheumatoid arthritic synovial fibroblastic E11 cells.Inhibition of CD200R1 expression by C/EBP β in reactive microglial cells.Histone deacetylase-3 activation promotes tumor necrosis factor-alpha (TNF-alpha) expression in cardiomyocytes during lipopolysaccharide stimulation.Combinatorial therapy with acetylation and methylation modifiers attenuates lung vascular hyperpermeability in endotoxemia-induced mouse inflammatory lung injury.Valproic acid: an anticonvulsant drug with potent antinociceptive and anti-inflammatory properties.O-GlcNAc transferase inhibits LPS-mediated expression of inducible nitric oxide synthase through an increased interaction with mSin3A in RAW264.7 cells.Dysregulated expression of miR-146a contributes to age-related dysfunction of macrophages.Histone deacetylase 2 (HDAC2) attenuates lipopolysaccharide (LPS)-induced inflammation by regulating PAI-1 expression.Histone deacetylase inhibitor, trichostatin A, improves learning and memory in high-fat diet-induced cognitive deficits in mice.Combination Therapies Targeting HDAC and IKK in Solid Tumors.Wheatgrass-Derived Polysaccharide Has Antiinflammatory, Anti-Oxidative and Anti-Apoptotic Effects on LPS-Induced Hepatic Injury in Mice.Mechanisms of NF-κB p65 and strategies for therapeutic manipulation
P2860
Q26768497-08BF0B36-E3F7-4D3E-A3EC-ACB8B4A518CEQ28076052-EBA89486-6B4E-4711-8D58-94D09EF34962Q30524207-1A7AD34D-C0C8-4CAE-AC78-536504DC19A2Q34048411-983140B7-AC1B-4EC7-B1B0-C6636EC7DE24Q34091848-531F68C0-F734-4DFC-8AB1-BC70F5D85071Q34559028-23A77984-C1B4-4646-9E22-E28AECB43351Q34635234-AC26BE00-AE00-4C32-AE12-5DFD934E04D8Q34651949-51BAB7C2-8A59-4CD7-AB2D-E496613D3F62Q35016934-E65BBA85-439B-4B0F-AD5E-40F22AAD6E55Q35969116-8F8B6FD5-7EC6-4C12-A914-E5C5E9776B58Q36972324-6EFD0682-4C30-43B9-B470-ABDFE342F087Q36972345-EB3B7BD1-0152-4D66-AF4A-06CC303F730DQ37848684-ACD2AF1E-47D6-4CA0-A367-0AF975929E61Q38935540-21B448A5-3437-4B2A-A127-C4044AA30956Q39062334-B398E8C1-38F8-407F-9DE3-D0FAACD539D7Q39317669-8D54F52F-BF08-41C4-9EFB-671592E5BF1CQ39738064-2ABC2DF9-1C00-4249-ABF3-C2D3309C0531Q42758806-571358FE-6FA1-4F57-9ECB-AAF0ED4FA146Q44674787-98CC0E71-C885-4208-9E05-814F80536563Q44745302-4E70B097-0C4F-49B2-A73F-35F724B6D4D4Q45154805-8C970610-39A8-47D1-BA63-951BC3979BC1Q47654382-8987DC5C-63A5-48A0-8072-10A3B56A3743Q48458054-39EB3598-FD3B-4343-A703-B431567AF093Q49887757-B7C0AD80-37E8-429F-A73D-B0293C54EA34Q50980407-DD3B24F7-DFE8-43AB-B147-134E15972FF8Q59125995-8CDE6A56-E474-483C-96E3-7F0FB11534EA
P2860
Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Histone deacetylase inhibitor ...... and in vivo endotoxemia model.
@en
Histone deacetylase inhibitor ...... and in vivo endotoxemia model.
@nl
type
label
Histone deacetylase inhibitor ...... and in vivo endotoxemia model.
@en
Histone deacetylase inhibitor ...... and in vivo endotoxemia model.
@nl
prefLabel
Histone deacetylase inhibitor ...... and in vivo endotoxemia model.
@en
Histone deacetylase inhibitor ...... and in vivo endotoxemia model.
@nl
P2093
P2860
P1476
Histone deacetylase inhibitor ...... and in vivo endotoxemia model.
@en
P2093
Gyoonhee Han
Hwan Mook Kim
Jee Sun Yang
Jeung Whan Han
Jong Soon Kang
Sang Bae Han
Song-Kyu Park
Yeo Dae Yoon
Yongseok Choi
P2860
P2888
P304
P356
10.3858/EMM.2008.40.5.574
P577
2008-10-01T00:00:00Z
P5875
P6179
1024711353